Evidence map›Paper›PMID 22332188›Full record

ArticleArchives of neurology2012

Prediction of cognitive decline by positron emission tomography of brain amyloid and tau.

Gary W Small, Prabha Siddarth, Vladimir Kepe, Linda M Ercoli, Alison C Burggren, Susan Y Bookheimer, Karen J Miller, Jeanne Kim, Helen Lavretsky, S-C Huang and 1 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Archives of neurology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 3 pooled it
8.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 3 syntheses or guidelines pooled it, 79 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Smoking and increased Alzheimer's disease risk: a review of potential mechanisms.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2014
    Pooled it
  4. [International psychogeriatrics · 2021
    Trial
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Modifiable Risk Factors and Brain Positron Emission Tomography Measures of Amyloid and Tau in Nondemented Adults with Memory Complaints.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2016
    Article
  19. Tau imaging in neurodegenerative diseases.European journal of nuclear medicine and molecular imaging · 2016
    Review
  20. Interaction of Cigarette Smoking History With APOE Genotype and Age on Amyloid Level, Glucose Metabolism, and Neurocognition in Cognitively Normal Elders.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Gary W SmallDepartment of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuroscience and Human Behavior, Los Angeles, CA 90024, USA. gsmall@mednet.ucla.edu
Prabha Siddarth
Vladimir Kepe
Linda M Ercoli
Alison C Burggren
Susan Y Bookheimer
Karen J Miller
Jeanne Kim
Helen Lavretsky
S-C Huang
Jorge R Barrio

Funding

UCLA Clinical and Translational Science InstituteUL1TR000124 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2012 to 2015
$57.0M
ZDV &3TC NEVIRAPINE COMBINATION THERAPY IN HIV 1 INFECTED INFANTS &M01RR000865 · NCRR · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WASHINGTON, ARNOLD E. · 1985 to 2011
$43.4M
UCLA ALZHEIMERS DISEASE RESEARCH CENTERP50AG016570 · NIA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI BREDESEN, DALE E. · 1999 to 2014
$25.9M
VISUALIZING BRAIN A-BETA, TAU /SEROTONIN RECEPTOR DENSITP01AG025831 · NIA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SMALL, GARY WILLIAM · 2005 to 2010
$7.0M
FUNCTIONAL MRI FOR EARLY DIAGNOSIS OF ALZHEIMER'SR01AG013308 · NIA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI BOOKHEIMER, SUSAN Y · 1995 to 2011
$4.5M
MENTAL DISORDERS OF AGING--ANTIINFLAMMATION IN ADR01MH058156 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SMALL, GARY WILLIAM · 1999 to 2003
$2.0M
Neurobiological Mechanisms of Treatment Response in Geriatric DepressionK24MH086481 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LAVRETSKY, HELEN · 2010 to 2014
$906k
INTERVENTION CLINICAL TRIAL FOR GERIATRIC DEPRESSIONK23MH001948 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LAVRETSKY, HELEN · 2001 to 2005
$835k
Effects of heavy adolescent cannabis use on brain morphology in agingK01DA034728 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI BURGGREN, ALISON CLEMENTS · 2013 to 2017
$776k
FUNCTIONAL BRAIN IMAGING AND MENTAL DISORDERS IN AGINGR01MH052453 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SMALL, GARY WILLIAM · 1995 to 1999
–
UCLA ALZHEIMERS DISEASE CENTERP30AG010123 · NIA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CUMMINGS, JEFFREY L. · 1991 to 1998
–
NCATS NIH HHS UL1 TR000124NCRR NIH HHS M01 RR000865NCRR NIH HHS M01-RR00865NIA NIH HHS AG13308NIA NIH HHS MH/AG58156NIA NIH HHS P01 AG025831NIA NIH HHS P01-AG025831NIA NIH HHS P30 AG010123NIA NIH HHS P50 AG016570NIA NIH HHS P50 AG 16570NIA NIH HHS R01 AG013308NIDA NIH HHS K01 DA034728NIMH NIH HHS K23 MH001948NIMH NIH HHS K24 MH086481NIMH NIH HHS MH52453NIMH NIH HHS R01 MH052453NIMH NIH HHS R01 MH058156
6 · The paper itself

Abstract

objectiveTo determine whether 2-(1-{6-[(2-fluorine 18-labeled fluoroethyl)methylamino]-2-napthyl}ethylidene) malononitrile ([(18)F]FDDNP) brain regional values in individuals without dementia predict and correlate with future cognitive change.

designTwo-year, longitudinal follow-up study.

settingA university research institute.

participantsVolunteer sample of 43 middle-aged and older persons (median age, 64 years), including 21 with mild cognitive impairment (MCI) and 22 with normal aging.

main outcome measuresLongitudinal [(18)F]FDDNP positron emission tomography (PET) binding values in the medial and lateral temporal, posterior cingulate, parietal, frontal, and global (mean) regions of interest; neuropsychological test battery measuring 5 cognitive domains, including memory, language, attention (and information-processing speed), executive functioning, and visuospatial ability.

resultsFor the entire study group (MCI and normal aging), increases in frontal, posterior cingulate, and global binding at follow-up correlated with progression of memory decline (r = -0.32 to -0.37, P = .03 to .01) after 2 years. Moreover, higher baseline [(18)F]FDDNP binding was associated with future decline in most cognitive domains, including language, attention, executive, and visuospatial abilities (r = -0.31 to -0.56, P = .05 to .002). For the MCI group, frontal and parietal [(18)F]FDDNP binding yielded the greatest diagnostic accuracy in identifying converters to Alzheimer disease vs nonconverters after 2 years, with an area under the receiver operating characteristic curve of 0.88 (95% CI, 0.72-1.00) compared with 0.68 (95% CI, 0.45-0.91) for medial temporal binding.

conclusions[(18)F]FDDNP PET regional binding patterns are consistent with known neuropathologic patterns of plaque and tangle brain accumulation, spreading from the medial temporal to other neocortical regions as disease progresses. Because binding patterns predict future cognitive decline and increase over time along with clinical decline, [(18)F]FDDNP PET scanning may have practical utility in identifying people at risk for future cognitive decline and in tracking the effectiveness of novel interventions designed to prevent or delay neurodegeneration and cognitive decline.

Indexed as

AdultAgedAged, 80 and overAmyloidogenic ProteinsBrain ChemistryCognition DisordersFemaleFollow-Up StudiesHumansImage Processing, Computer-AssistedIndolesIsoquinolinesLongitudinal StudiesMagnetic Resonance ImagingMaleMiddle Aged12-formyl-5,6-dihydro-3,9-dihydroxy-6-propylindolo(2,1-a)isoquinolineAmyloidogenic ProteinsIndolesIsoquinolinesRadiopharmaceuticalstau Proteins

Identifiers

PMID22332188
PMCPMC3623972
OpenAlexW2133813579

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.